David R Staskin
Overview
Explore the profile of David R Staskin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
578
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
MacDiarmid S, Staskin D, Lucente V, Kaaki B, English S, Gilling P, et al.
J Urol
. 2019 Apr;
201(5):967-972.
PMID: 31009968
Purpose: We performed a clinical feasibility trial to evaluate the safety and efficacy of a fully implanted, primary battery powered, nickel sized and shaped neuromodulation device called the eCoin® for...
2.
3.
Lucente V, Staskin D, De E
Open Access J Urol
. 2013 Nov;
3:35-42.
PMID: 24198634
Overactive bladder (OAB) is an age-related syndrome often associated with urinary incontinence. Symptoms of OAB, such as urgency, frequency, and nocturia, can be treated effectively with inhibitors of muscarinic acetylcholine...
4.
Kay G, Staskin D, MacDiarmid S, McIlwain M, Dahl N
Clin Drug Investig
. 2012 Aug;
32(10):707-14.
PMID: 22909146
Background And Objective: Oxybutynin is a common antimuscarinic therapy for overactive bladder. Transdermally administered oxybutynin chloride topical gel 10% (OTG) has a low propensity for anticholinergic adverse effects and possibly...
5.
Staskin D, Peters K, MacDiarmid S, Shore N, de Groat W
Curr Urol Rep
. 2012 Aug;
13(5):327-34.
PMID: 22893501
Overactive bladder affects millions of adults, with profound personal and economic costs. Although antimuscarinic drugs can cause a reduction in voiding symptoms, the effect is modest, and many patients are...
6.
7.
Staskin D, Michel M, Sun F, Guan Z, Morrow J
J Urol
. 2012 Mar;
187(5):1721-6.
PMID: 22425113
Purpose: We analyzed the effects of baseline symptom severity and placebo response magnitude on the decision to dose escalate in a 12-week, randomized, double-blind, flexible dose antimuscarinic trial of subjects...
8.
Chancellor M, Staskin D, Kay G, Sandage B, Oefelein M, Tsao J
Drugs Aging
. 2012 Mar;
29(4):259-73.
PMID: 22390261
Overactive bladder (OAB) is a common condition, particularly in the elderly. Anticholinergic agents are the mainstay of pharmacological treatment of OAB; however, many anticholinergics can cross the blood-brain barrier (BBB)...
9.
Zinner N, Dmochowski R, Staskin D, Siami P, Sand P, Oefelein M
Neurourol Urodyn
. 2011 Apr;
30(7):1214-9.
PMID: 21462240
Aims: Once-daily extended-release (XR) trospium chloride has been evaluated for the treatment of overactive bladder syndrome (OAB) in two 12-week randomized, double-blind, placebo-controlled studies. This pooled analysis of the 9-month...
10.
Starkman J, Smith C, Staskin D
Rev Urol
. 2010 Sep;
12(2-3):e97-e110.
PMID: 20811558
Overactive bladder (OAB) is a symptom complex of urinary frequency, urinary urgency, and nocturia, with or without urgency incontinence. This syndrome is idiopathic in most instances without clearly defined pathophysiology....